[{"orgOrder":0,"company":"Bio Farma","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Sinovac Biotech"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Universitas Padjadjaran | NIHRD, Ministry of Health, Indonesia | Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Universitas Padjadjaran | NIHRD, Ministry of Health, Indonesia | Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Universitas Padjadjaran | NIHRD, Ministry of Health, Indonesia | Sinovac Biotech"},{"orgOrder":0,"company":"Bio Farma","sponsor":"University of Indonesia | Diponegoro University | Andalas University | Hasanuddin University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ University of Indonesia | Diponegoro University | Andalas University | Hasanuddin University","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ University of Indonesia | Diponegoro University | Andalas University | Hasanuddin University"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Rotavirus RV3 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Lead Product(s) : COVID-19 Protein Subunit Recombinant Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase III

                          Sponsor : University of Indonesia | Diponegoro University | Andalas University | Hasanuddin University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : COVID-19 Protein Subunit Recombinant Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          June 27, 2022

                          Lead Product(s) : COVID-19 Protein Subunit Recombinant Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : University of Indonesia | Diponegoro University | Andalas University | Hasanuddin University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Lead Product(s) : Inactivated SARS-CoV-2 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase III

                          Sponsor : Universitas Padjadjaran | NIHRD, Ministry of Health, Indonesia | Sinovac Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Inactivated SARS-CoV-2 vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 11, 2020

                          Lead Product(s) : Inactivated SARS-CoV-2 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Universitas Padjadjaran | NIHRD, Ministry of Health, Indonesia | Sinovac Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : In the clinical trial of the 3 Covid-19 vaccines, Bio Farma will work together with the Phase 3 Clinical Trial Research Team, Faculty of Medicine, UNPAD Bandung for the next six months. If the Phase 3 clinical trial goes well, then the next step is to re...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 08, 2020

                          Lead Product(s) : COVID-19 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Sinovac Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Bio Farma (Rotavirus RV3 Vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroenteritis.

                          Product Name : Bio Farma

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 04, 2019

                          Lead Product(s) : Rotavirus RV3 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank